Authors
Laura Danner, Anja Pammer, Melanie Kienzl, Dusica Ristic, Alfred D Doyle, Benjamin L Wright, Franziska Baumann-Durchschein, Julia Konrad, Andreas Blesl, Hansjörg Schlager, Thomas Bärnthaler, Eva Böhm, Armin Zebisch, Rudolf Schicho, Eva Gruden
Published in
Journal of immunology (Baltimore, Md. : 1950). Volume 215. Issue 11. Nov 02, 2026.
Abstract
Allergic diseases remain a major clinical challenge because current treatments, such as antihistamines and corticosteroids, provide only symptomatic relief without addressing the underlying immune dysregulation. Induction of regulatory T cells (Tregs) to generate allergen tolerance has recently emerged as a potential form of therapy. Similarly, investigating the mechanisms and medical potential of the endocannabinoid system has become more popular in recent years. In particular, the CB2 receptor, which is most abundant in peripheral tissues and immune cells, offers a potential target for immunomodulation. In this study, we examined expression patterns of CB2 in atopic and nonatopic donors and investigated the effects of CB2 ligands and CB2 deficiency on immune cells in vitro and in vivo. We observed significantly decreased CB2 expression on CD4+ T cells from atopic donors, with expression levels positively correlating with Treg abundance. Furthermore, CB2 agonists and antagonists altered immune cell migration and differentiation, effects that were absent in CB2 knockout mice. Blocking the CB2 receptor in human CD4+ T cells decreased endogenous TGF-β secretion and downregulated IL-10 mRNA expression. Our study provides new insights into the effects of CB2 on human naïve CD4+ T cells and warrants further investigation of CB2-targeting compounds as potential adjuvants for allergen-specific immunotherapy.
PMID:
43033824
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0